Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

Summary

The main purpose of this trial is to determine whether Xingnaojing, intravenously administered within 24 hours of symptom onset, improves the 3-month outcome in participants with acute ischemic stroke.

Conditions

• Acute Ischemic Stroke

Interventions

DRUG

Xingnaojing injection

Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.

OTHER

Standard care

Guidelines-based standard care for acute ischemic stroke.

Sponsors & Collaborators

• Beijing Tiantan Hospital

  collaborator OTHER

• Beijing Chao Yang Hospital

  collaborator OTHER

• Guangdong Provincial Hospital of Traditional Chinese Medicine

  collaborator OTHER

• The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

  collaborator OTHER

• Beijing Emergency Medical Center

  collaborator OTHER

• The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

  collaborator UNKNOWN

• Deyang People's Hospital

  collaborator OTHER

• The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

  collaborator OTHER

• The Second Hospital of Hebei Medical University

  collaborator OTHER

• The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

  collaborator OTHER

• Hunan Academy of Chinese Medicine

  collaborator UNKNOWN

• The First Hospital of Jilin University

  collaborator OTHER

• China-Japan Union Hospital, Jilin University

  collaborator OTHER

• Jiangmen Wuyi Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Jiangxi Provincial People's Hopital

  collaborator OTHER

• Mianyang Central Hospital

  collaborator OTHER

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

  collaborator OTHER

• Shandong University of Traditional Chinese Medicine

  collaborator OTHER

• Shaanxi Provincial People's Hospital

  collaborator OTHER

• Shaanxi Provincial Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• The Affiliated Hospital of Shaanxi University of Chinese Medicine

  collaborator UNKNOWN

• Tianshui Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Wuxi Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• The First Hospital of Wuhan

  collaborator UNKNOWN

• Zhejiang Provincial Tongde Hospital

  collaborator OTHER

• Zhejiang Provincial Hospital of TCM

  collaborator OTHER

• Zhongshan Hospital Of Traditional Chinese Medicine

  collaborator OTHER

• The Fifth People Hospital of Chongqing

  collaborator UNKNOWN

• Chongqing Traditional Chinese Medicine Hospital

  collaborator OTHER

• Zibo Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Liling Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Cangzhou Hospital of Integrated Medicine

  collaborator UNKNOWN

• Yantai Yuhuangding Hospital

  collaborator OTHER

• Dongzhimen Hospital, Beijing

  lead OTHER

Principal Investigators

• Ying Gao, MD · Dongzhimen Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

35 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-03-31

Primary Completion

2019-12-31

Completion

2019-12-31

Countries

• China

Study Locations